Kyle’s practice focuses on mergers & acquisitions, including cross-border transactions, carve outs, joint ventures, divestitures and other complex corporate transactions. He has represented public and private companies across a diverse range of industries, and he has significant experience counseling clients on corporate governance and securities law matters.
Y-mAbs Therapeutics Agrees to Acquisition by SERB Pharmaceuticals
August 5, 2025
Cooley advised Y-mAbs Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, on its definitive merger agreement with SERB Pharmaceuticals. Under the agreement, SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA, in an all-cash transaction representing an equity value of approximately $412 million.
Cooley advised Movable Ink, an artificial intelligence-powered personalized content platform, on its definitive agreement to be acquired by STG. The transaction is expected to close in July 2025.
SKIMS Acquires SKKN by Kim From Kim Kardashian and Coty
March 21, 2025
Cooley advised Kim Kardashian, an American media personality, socialite and businesswoman, on SKIMS’ acquisition of SKKN by Kim, a beauty, skincare, and fragrance brand she founded, including the 20% stake held by Coty.
Araris Biotech’s up to $1.14 Billion Acquisition by Taiho Pharmaceutical
March 17, 2025
Cooley advised Araris Biotech, a Swiss biotechnology company developing next-generation antibody-drug conjugates, on its definitive agreement to be acquired by Japan-based Taiho Pharmaceutical for up to $1.14 billion in cash.
Cooley Advises Special Committee of Checkpoint on Acquisition by Sun Pharma
March 9, 2025
Cooley advised the special committee of Checkpoint Therapeutics’ (Nasdaq: CKPT) board of directors in connection with Checkpoint’s definitive agreement to be acquired by Sun Pharmaceutical Industries (NSE: SUNPHARMA) for up to $416 million in cash and contingent value rights.